|
|
News Breaks | | | | January 31, 2013 | | 05:50 EDT |  | AZN | AstraZeneca reports Q4 core EPS $1.56, consensus $1.41
Reports Q4 revenue $7.28B, consensus $7.17B. Reports Q4 Nexium revenue $1.05B vs. $1.07B a year ago, Crestor revenue $1.62B vs. $1.77B a year ago, Symbicort revenue $891M vs. $839M a year ago. | |
|
News For AZN From The Last 14 Days Check below for free stories on AZN the last two weeks. |
|
|
| May 17, 2013 | | 10:36 EDT |  | AZN | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
 Subscribe for More Information | | | 08:41 EDT |  | AZN | Impax commenced shipment of authorized generic Zomig
Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. | | | May 14, 2013 | | 07:24 EDT | | AZN | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. | | | May 13, 2013 | | 16:53 EDT |  | AZN | Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says
Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link | | | 15:55 EDT | | AZN | Optimer gets first round bids from AstraZeneca, Cubist, Bloomberg says
Subscribe for More Information | | | May 10, 2013 | | 11:48 EDT | | AZN | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information | | | May 9, 2013 | | 10:17 EDT | | AZN | Shire trades higher in London amid takeover chatter, Guardian says
Subscribe for More Information | | | May 6, 2013 | | 16:23 EDT | | AZN | Array to start first company-led Phase 3 trial with MEK162
Array (ARRY) announced the planned start of its first company-led Phase 3 trial with MEK162 in low-grade serous ovarian cancer. This is the third MEK162 pivotal trial that is expected to initiate in 2013 and one of five pivotal trials Array expects to begin in 2013 on Array-invented products. Novartis (NVS), who is co-developing MEK162 with Array, previously stated that Phase 3 trials in NRAS-mutant melanoma and BRAF-mutant melanoma are expected to start this year and AstraZeneca has announced its plans to initiate two registration trials with selumetinib, a MEK inhibitor invente (AZN) d by Array, in KRAS-mutant non-small cell lung cancer and in thyroid cancer. Array also recently released initial data on its wholly-owned hematology drug, ARRY-520, from a combination trial with VelcadeŽ (bortezomib) in patients with relapsed or refractory multiple myeloma (MM), showing that the drug was generally well-tolerated and showed initial signs of activity in this heavily pretreated population. | | | 13:16 EDT | | AZN | AstraZeneca management to meet with Jefferies
Meeting to be held in New York on May 9 hosted by Jefferies. | | | 07:27 EDT | | AZN | Bristol-Myers, AstraZeneca announces results of metreleptin study
Subscribe for More Information | | |
|
|
|
|
|
|
